ERBB2 and breast cancer: For example, HR-positive/HER2-positive BC patients show a lower risk of relapse in the first 3–5 years after diagnosis as compared to patients with HR-negative/HER2-positive BC, however, the risk of relapse may persist longer at a later follow-up5,6.